Skip to content
← All settings

DISEASE & TREATMENT SETTING

XELODA: unresectable metastatic Rectal cancer (adjuvant)

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.1 Colorectal Cancer XELODA is indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen.

Broader topic: Rectal Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
adjuvant
Stage
Not part of this definition
Resectability
unresectable
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from the FDA approved indication for XELODA (product label). Only dimensions stated in that wording are part of this definition.
      source wording
      1.1 Colorectal Cancer XELODA is indicated for the: adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen.

      Study evidence for this setting

      6 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice